LatestBreast Cancer Survivors May Stop Heart Medication After Recovery, Study Shows
Health

'El Fenómeno' Cruz Takes Serious Approach to López Bout Despite Past Prime Years

Carlos González
'El Fenómeno' Cruz Takes Serious Approach to López Bout Despite Past Prime Years
Summary

Puerto Rican boxer Orlando 'El Fenómeno' Cruz prepares for his long-awaited matchup against Juan Manuel 'Juanma' López on August 29th. The rivalry between the two fighters has been brewing for years within professional boxing circles. Though both competitors are in their later career stages, Cruz remains committed to the bout. This fight represents a significant moment for Puerto Rican boxing fans eager to see this rivalry finally resolved in the ring.

Originally published on

NotiCel

By Carlos González

Read full article(opens in new tab)

Fetched: August 27, 2026 at 10:01 AM

Related News

More news you might be interested in

View all
Breast Cancer Survivors May Stop Heart Medication After Recovery, Study Shows
Health
CancerHeart Disease

Breast Cancer Survivors May Stop Heart Medication After Recovery, Study Shows

A new study presented at the European Society of Cardiology Congress reveals that many breast cancer survivors who developed heart problems from their treatment can safely discontinue cardiac medication once their heart function recovers. The research indicates that most survivors won't require lifelong heart medication, offering hope for improved quality of life and reduced medication burden. This finding is significant because certain cancer treatments, particularly chemotherapy and targeted therapies, can cause cardiotoxicity as a side effect. The study suggests patients should work with their oncology and cardiology teams to monitor heart recovery and determine when medication can be safely stopped, rather than assuming permanent treatment is necessary.

11 hours ago
Medical Xpress
Cardiologist Referrals Improve Cholesterol in Prostate Cancer Patients, But May Not Prevent Heart Events
Health
CancerHigh Cholesterol

Cardiologist Referrals Improve Cholesterol in Prostate Cancer Patients, But May Not Prevent Heart Events

A landmark international study led by Hamilton researchers found that routine referrals to cardiologists or internists improved cholesterol levels in prostate cancer patients treated with hormone therapy, but did not reduce the incidence of heart attacks, strokes, heart failure, or cardiovascular deaths. Men with prostate cancer face elevated cardiovascular risk, particularly when undergoing hormone therapy as part of their cancer treatment. While cholesterol management remains important, this finding suggests that not all prostate cancer patients may require routine specialist cardiac referrals. Healthcare providers may need to reconsider screening protocols and individualize cardiac care for this patient population.

11 hours ago
Medical Xpress
Early Statin Use After Type 2 Diabetes Diagnosis Linked to Lower Dementia Risk
Health
Alzheimer's DiseaseHigh Cholesterol

Early Statin Use After Type 2 Diabetes Diagnosis Linked to Lower Dementia Risk

A new study presented at ESC Congress 2026 and published in The Lancet Regional Health – Europe reveals that initiating statin therapy shortly after a type 2 diabetes diagnosis is associated with a significantly reduced risk of developing dementia. People with type 2 diabetes face elevated risks for both cardiovascular disease and cognitive decline, making this finding particularly significant for disease management. Statins, commonly prescribed cholesterol-lowering medications, may offer protective benefits beyond their traditional cardiovascular effects. This research suggests that early statin initiation could represent an important preventive strategy for diabetic patients concerned about cognitive health.

13 hours ago
Medical Xpress
Twice-Daily Radiation Linked to Better Quality of Life in Lung Cancer Trial
Health
Cancer

Twice-Daily Radiation Linked to Better Quality of Life in Lung Cancer Trial

The NRG-LU005 study evaluated adding the immunotherapy drug atezolizumab (Tecentriq) to standard concurrent chemoradiation for limited-stage small-cell lung cancer. While the addition of atezolizumab did not improve overall survival, the trial revealed that twice-daily radiation therapy was associated with significant improvements in patients' quality of life. These secondary findings suggest that radiation dosing schedules may play an important role in treatment outcomes beyond survival metrics. The results highlight the importance of considering patient well-being and functional status alongside traditional survival measures in cancer treatment planning.

19 hours ago
Medical Xpress